Clinical Trials Directory

Trials / Completed

CompletedNCT06047210

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

An Observational, Multicenter Study to Evaluate Levels of Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Adult Patients With Hemophagocytic Lymphohistiocytosis (A-HLH)

Status
Completed
Phase
Study type
Observational
Enrollment
14 (actual)
Sponsor
Swedish Orphan Biovitrum · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.

Detailed description

This is a observational study designed to determine the levels of pro-inflammatory markers in adult patients diagnosed with HLH and to assess the relationship between the biomarkers and disease activity in these patients during the HLH course. Inflammatory markers include IFNγ and IFNγ-induced chemokines C-X-C chemokine ligand 9 and C-X-C chemokine ligand 10. In addition to the blood samples for the biomarker analysis, relevant information gathered by the treating physician will be collected in a data collection form. Whenever possible, collection of serum samples for biomarker analysis and relevant information should occur at HLH diagnosis, at regular time intervals during the treatment course (not more than once a week) up to resolution of HLH. Blood samples will also be sent to the study sponsor (NovImmune S.A.) for cytokine testing. Before patient's samples are sent to the sponsor for testing, patient's name and any personal identifying information will be coded to protect participant's privacy.

Conditions

Interventions

TypeNameDescription
OTHERBlood Draws Data Collection

Timeline

Start date
2016-12-14
Primary completion
2019-10-30
Completion
2019-10-30
First posted
2023-09-21
Last updated
2024-09-19
Results posted
2024-09-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06047210. Inclusion in this directory is not an endorsement.